Treatment trial with Losartan of a patient with stiff skin syndrome.

Treatment trial with Losartan of a patient with stiff skin syndrome. - Treatment trial of stiff skin syndrome with Losartan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36060

Enrollment

Registered

2011-07-25

Start date

2011-09-16

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital scleroderma stiff skin syndrome

Interventions

Treatment with the maximal tolerated dose till a maximum of 100 mg Losartan during 3 months.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis of stiff skin syndrome.

Exclusion criteria

Exclusion criteria: Pregnancy.

Design outcomes

Primary

Measure	Time frame
1. Improvement of joint excursions. 2. Improvement of the hardening of the skin. 3. Change of fibrosis in the skin. 4. Change of the TGFβ signaling	—

Secondary

Measure	Time frame
Side effects of Losartan	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)